DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20193426

Psychopharmacology in myasthenia gravis patients with focus on depression

Ida Bagus Gede Wisnu Wardhana, Anak Ayu Sri Wahyuni, Komang Arimbawa

Abstract


Myasthenia gravis is an autoimmune disease with a potential to disrupt brain function and cause depression as a result of the disease itself or treatment side effect. Some biological and psychological mechanisms have been proposed for the correlations between myasthenia gravis and depression. Depression might present in patients myasthenia gravis, and it might complicate the course of the disease. Adequate treatment might not only improve the depression but might also impact the myasthenia gravis in general.


Keywords


Contraindication, Depression, Myasthenia gravis, Psychopharmacology, Side effect, Treatment

Full Text:

PDF

References


Shah AK, Goldenberg WD. Myasthenia gravis New York: MedScape; 2016. Available at: http://emedicine.medscape.com/article/1. Accessed 24 March 2019.

Mourao AM, Gomez RS, Barbosa LSM, Freitas DdS, Comini-Frota ER, Kummer A, et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics. 2016;71(7):370-4.

Freeman C, Lewis I, Heckmann JM. Neuropsychiatric symptoms in patients with thymoma-associated and non-thymoma myasthenia gravis. S Afr J Psych. 2014;20(2):50-3.

Aguinaldo JL, de Guzman R. The Effectiveness of Logo-Bibliotherapy on the Depression of Selected Filipino Suffering from Myasthenia Gravis. Asian J Natural Appl Sci. 2014;3(2):31-9.

Jones SM, Gwathmey KG, Burns TM. Quality of life measures for myasthenia gravis and evaluation of non-motor symptoms. Clin Exp Neuroimmunol. 2015;6(1):32-9.

Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So, depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11(200):1-16.

Hamed SA. Comorbid nervous system manifestations and disorders with myasthenia gravis: Evidences and possible mechanisms. J Neurol Neuro Sci. 2012;3(1):1-17.

Aysal F, Karamustafalioglu O, Ozcelik B, Yilmaz M, Karamustafalioglu N. The Relationship of Symptoms of Anxiety and Depression with Disease Severity and Treatment Modality in Myasthenia Gravis: A Cross-sectional Study. Noro Psikiyatr Ars. 2013;50(4):295-300.

Ybarra MI, Kummer A, Frota ERC, de Oliveira JT, Gomez RS, Teixeira AL. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr. 2011;69(2-A):176-9.

Leon-Sarmiento FE, Bayona EA, Bayona-Prieto J, Osman A, Doty RL. Profound Olfactory Dysfunction in Myasthenia Gravis. Plos One. 2012;7(10):1-5.

Ouanes S, Hizem Y, Djebara MB, Kacem I, Gargouri A, Gouider R. Differential Diagnosis of Hallucinations in a Patient with Myasthenia Gravis. Innov Clin Neurosci. 2013;10(9-10):23-5.

Halverson JL. Available at: http://www.medscape.com/ 2015. Accessed 18 June 2015.

Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety-and depression-like behavior. Proc Natl Acad Sci U S A. 2013;110(9):3573-8.

Nikkheslat N, Zunszain PA, Horowitz MA, Barbosa IG, Parker JA, Myint, et al. Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain, Behav, Immun. 2015;48:8-18.

Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BWJH. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: Findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinol. 2013;38(9):1573-85.

Pandey GN, Dwivedi Y. Peripheral Biological Markers for Mood Disorders. In: Ritsner MS, editor. The Handbook of Neuropsychiatric Biomarkers, Endophenotypes, and Genes Volume III. Berlin: Springer; 2009: 121-149.

Vogelzangs N, Duivis H, Beekman A, Kluft C, Neuteboom J, Hoogendijk W, et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry. 2012;2(2):e79.

Abukhalil F, Mehta B, Saito E, Mehta S, McMurtray A. Gender and Ethnicity Based Differences in Clinical and Laboratory Features of Myasthenia Gravis. Autoimmune Dis. 2015;1-4.

Vaillant AAJ, Mohammed W, Vuma S, Anderson N. Autoimmunity in Neurological and Psychiatric Disorders: Participation of Antibodies and Cytokines in the Immunopathogenesis of these Diseases. Immunome Res. 2015;11(1):1-4.

Kovacs D, Kovacs P, Eszlari N, Gonda X, Juhasz G. Psychological side effects of immune therapies: symptoms and pathomechanism. Curr Opinion Pharmacol. 2016;29:97-103.

Mourão AM, Araújo CM, Barbosa LSM, Gomez RS, Burns TM, Lemos SMA, et al. Brazilian cross-cultural translation and adaptation of the Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items. Arq Neuropsiquiatr. 2013;71(12):955-8.

Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, et al. An up-date on health-related quality of life in myasthenia gravis -results from population-based cohorts. Health Quality Life Outcomes. 2015;13(115):1-14.

Ahmed A, Simmons A. Drugs Which MAy Exacerbate or Induce Myasthenia Gravis: A Clinician's Guide. Internet J Neurol. 2009;10(2).

Levin ED, Rezvani AH. Nicotinic Interactions with Antipsychotic Drugs, Models of Schizophrenia and Impacts on Cognitive Function. Bioch Pharmacol. 2009;74(8):1182-91.

Morais M, Pinheiro A, Patricio P, Alves N, Pinto L, Sousa N, et al. The Impact of Antipsychotic Drugs in Depression: A Role for Adult Neurogenesis? Neurosciences Res. 2014;24:448.

National Center for Biotechnology Information. PubChem Compound Database. 2019. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/2789. Accessed 14 March 2019.